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Abstract 1 
Background 2 
There is evidence to suggest that adherence with prescribed medication is lower amongst 3 
adolescents and children than in adults (1). Medication adherence rates between 11% and 93% in 4 
paediatric patients have been reported (2). More research needs to be carried out in order to 5 
understand why medicines adherence is low and how adherence can be improved in children with 6 
long-term conditions. Personal communication with paediatricians in secondary care has highlighted 7 
that problems are most likely to be encountered by parents, carers, nurses and children themselves 8 
when administering medicines for prevalent long-term childhood conditions. 9 
 10 
Objective 11 
To explore problems with oral medicines prescribed to paediatric patients from the perspectives of 12 
medical practitioners, pharmacists and nurses. 13 
 14 
Setting 15 
Two NHS trusts in the West Midlands, UK 16 
 17 
Method 18 
Four focus groups (FG) were conducted. 5 nurses, 8 medical practitioners and 6 pharmacists 19 
participated in focus groups.. The themes explored were problems experienced when prescribing, 20 
dispensing and administering oral medicines for children. Ethical approval was granted by the South 21 
Birmingham Research Ethics Committee (REC), UK. 22 
 23 
Main outcome measure  24 
Themes evolving from Healthcare professionals reports on problems with administering medicines 25 
to paediatric patients. 26 
 27 
Results 28 
Two main themes: sensory and non-sensory emerged from the data. Included within these were 29 
taste, texture, colour, smell, size, swallowing, quantity, volume and manipulation with food. Taste 30 
was the most commonly reported barrier to medicines administration. Texture was reported to be a 31 
significant problem for the learning disability population. Medicines manipulation techniques were 32 
revealed across the groups, yet there was limited knowledge regarding the evidence base for such 33 
activity. Problems surrounding the supply of Specials medicines were discussed in-depth by the 34 
pharmacists. 35 
 36 
Conclusion 37 
Organoleptic and physical properties of medicines were identified as key barriers to medicines 38 
administration. A robust scientific evidence-based approach is warranted to inform standardised 39 
protocols guiding healthcare professionals to support safe and effective medicines manipulation 40 
across all settings. Pharmacists' knowledge of Specials medicines needs to be recognised as a 41 
valuable resource for doctors. Findings of this study should help to optimise paediatric prescribing 42 
and direct future formulation work. 43 
 44 
Keywords: pediatrics;healthcare professionals;medicines administration;medicines 45 
adherence;prescribing. 46 
 47 
 A large number of issues are perceived by healthcare professionals to cause problems when 48 
administering oral medicines to children. Taste was highlighted as the most significant issue. 49 
 50 
 Nurses had the greatest knowledge of bedside issues, whilst pharmacists understood the 51 
consequences of certain manipulations; wider sharing of this knowledge can help to ensure 52 
appropriate medicines are prescribed to minimise issues with administration.  53 
 54 
 The scientific evidence base for medicines manipulation requires further development; it is 55 
evident that medical practitioners require more information when prescribing medicines to 56 
ensure supply, clinical effectiveness and to maximise cost efficiency. 57 
 58 
 Addressing the education of healthcare professionals involved in prescribing, dispensing and 59 
administering oral medicines to children will be invaluable to improving the therapeutic 60 
treatment of paediatric patients. 61 
 62 
Ethical Approval 63 
Ethical approval was granted by the South Birmingham REC, UK (REC no: 10/H1207/47). 64 
 65 
Introduction  66 
There is evidence to suggest that adherence with prescribed medication is lower amongst 67 
adolescents and children (0-17 years) than in adults (1). Medication adherence rates between 11% 68 
and 93% in paediatric patients have been reported (2). A median rate of 58% medicine adherence in 69 
youth has been estimated (3). As one in five children in the UK has a long standing illness or disability 70 
(4) it is critical that more research needs to be carried out in order to understand why medicines 71 
adherence is low and how adherence can be improved in children with long-term conditions. 72 
Personal communication with paediatricians in secondary care has highlighted that problems are 73 
most likely to be encountered by parents, carers, nurses and children themselves when having to 74 
administer medication for prevalent long-term childhood conditions, notably: diabetes, Human 75 
immunodeficiency virus (HIV), asthma, Tuberculosis (TB), rheumatic diseases amongst others. It is 76 
predicted that issues experienced with medicines will be influenced by the child’s age and disease 77 
state. 78 
Problems with children’s medicines may be influenced by many factors. These include issues with 79 
prescribing and the supply of medicines, the prevalence of unlicensed medicines and medicines 80 
prescribed off-label (5,6), difficulties with administering medicines (including manipulation of 81 
medicines – 7,8), behaviour around medicine taking (including influence of family, school and life 82 
situation) (9), adverse effects of medicines and medicine adherence problems in specific patient 83 
groups (i.e. age groups and chronic conditions). Particularly, research on juvenile diabetes, 84 
haemophilia and rheumatoid arthritis has revealed the potential vulnerability of young people to 85 
medication non-adherence (10). 86 
Anecdotal parental reports suggest that healthcare professionals may not be aware of the specific 87 
barriers and problems that patients and their parents and carers perceive and experience daily when 88 
administering medicines to children. Medicines may be manipulated by parents, carers and young 89 
people for which there is often a lack of robust scientific evidence. Parents, carers and young people 90 
may decide to manipulate medicines of their own accord, unbeknown to the responsible medical 91 
practitioner. Alternatively medicines manipulation may be performed following a recommendation 92 
from a healthcare professional. 93 
There is a paucity of research investigating healthcare professionals’ perceptions of issues with 94 
medicines used to treat paediatric patients with chronic conditions. Studies that have been 95 
conducted include an exploration of healthcare providers’ views on HIV adherence in paediatric 96 
patients (11), an investigation in to nurses’ knowledge and practice of mixing medicines with 97 
foodstuffs (12) and those investigating unlicensed medicines use  (13,14). The present study aimed 98 
to have a more diverse approach, exploring the perspectives of allied healthcare professionals 99 
(medical practitioners, nurses and pharmacists) with regard to problems with oral medicines 100 
prescribed to children. 101 
Aim of the study 102 
The objective of the focus groups was to explore and understand the problems experienced when 103 
prescribing, dispensing and administering oral medicines to children from the perspectives of 104 
medical practitioners, pharmacists and nurses. The aim of this was to identify common and unique 105 
themes across healthcare professional groups regarding problems with oral medicines prescribed to 106 
paediatric patients and furthermore to compare their views with those of parents, carers and 107 
children in the second part of the larger FIND OUT study (REC no: 10/H1207/47). 108 
Method 109 
Initial ideas generated by RV with the advice of the Professor of Clinical Pharmacy (JM) and a 110 
Consultant Paediatrician (HS) were informed by healthcare professionals in pre-study hospital visits 111 
and by study objectives. The different professional backgrounds of the individuals involved in study 112 
design permitted the collaboration of a clinical and pharmaceutical input. Ideas were used to 113 
develop a template plan of key topics for exploration in the focus groups. The same key topics 114 
surrounding problems with oral medicines in children were highlighted in each focus group to 115 
provoke participant interaction and discussion in the groups.  116 
Children suffering from chronic conditions often have regular appointments in the secondary care 117 
setting to review their condition and medicines. In the hospital environment, different members of 118 
the healthcare team are responsible for providing care for patients. This multidisciplinary healthcare 119 
team includes medical practitioners, nurses and pharmacists of varying expertise and with different 120 
specialist interests. 121 
This study was conducted with healthcare professionals at University Hospitals Coventry and 122 
Warwickshire (UHCW) and Birmingham Children’s Hospital (BCH), UK. Healthcare professionals were 123 
invited to join a focus group by posters mounted on walls at UHCW and also contacted via the 124 
UHCW email system and invited to respond to register an interest to participate. In addition, 125 
targeted emails were sent to paediatric pharmacists in the West Midlands region. An information 126 
sheet designed using guidance from the National Patient Safety Agency (NPSA) (15) was distributed 127 
with the invitation email. General Practitioners (GPs) in Coventry and Warwickshire were informed 128 
of the study via a study summary article in the clinical pharmacology e-newsletter, routinely 129 
disseminated to all GPs in Coventry and Warwickshire.  130 
 131 
Four uniprofessional focus groups were conducted involving nurses, medical practitioners, 132 
pharmacists at UHCW, and a further group of pharmacists at BCH. The four focus groups were 133 
conducted between September 2010 and February 2011. The second pharmacist focus group was 134 
arranged for pharmacists at BCH. These pharmacists had generated interest in the study but were 135 
unable to attend the UHCW session for logistical reasons.The introduction for each focus group 136 
followed the same structure and included obtaining written consent from each participant to permit 137 
publication of anonymised quotations, followed by a reminder about confidentiality issues. The 138 
planning and conducting stages of the focus group sessions were carried out according to defined 139 
procedures (16). Focus group design was informed by anecdotal information from parents, children 140 
and healthcare professionals. The four focus groups were facilitated by RV and assisted by JM/HS. 141 
The groups were digitally audio-recorded and complementary notes were taken during the sessions.  142 
 143 
RV transcribed each focus group. Complementary notes recorded during the sessions were used to 144 
optimise accuracy of the verbatim transcripts. The focus groups data was analysed using a 145 
framework analysis approach, following published guidance (17). The template plan of topics was 146 
used to explore and identify the themes revealed in each transcript. Following this, common themes 147 
revealed across the groups and those unique to each group were identified. The thematic analysis 148 
program QSR NVivo supported this analysis. 149 
 150 
Results  151 
Four focus groups were conducted with the following healthcare professionals: 152 
1. Nurses  (n=5: Neonatal nurse practitioners (n=2), a nurse with a specialist interest in CF, a 153 
community-based nurse and a nurse practice educator), 154 
2. Medical practitioners (n=8: Paediatric consultants with specialist interests (n=6), a paediatric 155 
specialist registrar, and a GP with an interest in paediatrics) 156 
3. Paediatric pharmacists (n=2) 157 
4. Paediatric pharmacists (n=4). 158 
 159 
Focus groups 1-3 were conducted at UHCW. Focus group 4 was conducted at BCH. The nurse and 160 
medical practitioner groups were conducted at lunchtime and the pharmacist groups took place in 161 
allocated study time. Groups lasted between 51 and 93 minutes.  162 
 163 
Following the framework analysis, a structured thematic coding spine (see table 1) was created 164 
based on two main themes: sensory and non-sensory (social and situational).  Ten sub-themes 165 
emerged from the focus groups. The coding spine includes themes revealed both independently and 166 
across the focus groups. The results of the analysis are discussed systematically, using the thematic 167 
headings and sub-headings listed in table 1. 168 
 169 
Sensory themes 170 
Oral formulation-related barriers to medicines administration 171 
Commonly reported oral formulation-related barriers to the acceptance of medicines in children 172 
across the four focus groups included taste, texture, size of solid dosage form, and volume. Taste 173 
was the most prevalent oral formulation-related problem highlighted across the groups. 174 
Flucloxacillin solution was perceived by all healthcare professional groups to be disliked by children 175 
due to its taste. 176 
 177 
Chloral hydrate solution, prednisolone soluble tablets and Movicol® (macrogol ‘3350’) oral powder 178 
were all highlighted with respect to taste in two of the focus groups. 179 
 180 
Taste issues with specific formulations revealed in the focus groups in table 1. 181 
 182 
All medicines reported with taste problems in the focus groups were perceived by participants to 183 
cause problems with adherence.  184 
 185 
All of the healthcare professional groups highlighted that children experience problems with the 186 
textures of some medicines. The learning disability population were discussed as a problematic 187 
patient population across the focus groups when regarding problems with texture. 188 
All groups acknowledged that children taking antiretroviral tablets experience problems with their 189 
size and also difficulties when swallowing them. In particular, Kaletra® (lopinavir/ritonavir) tablets 190 
were mentioned to be problematic. Additionally, large dose volumes were perceived to be a barrier 191 
to medicines administration and examples of formulations with large dose volumes were 192 
volunteered across the groups. 193 
The nurses reported the widest variety of oral formulation-related barriers to medicines 194 
administration including those that affect sensory perceptions (colour and smell).  195 
Future medicines for children 196 
The nurses and medical practitioners prioritised the improvement of a variety of poorly palatable 197 
medicines. However, the pharmacists perceived that an improvement to Specials medicines would 198 
be ideal. In the UK, Healthcare professionals may consider it necessary to prescribe or advise the use 199 
of an unlicensed medicine when no licensed, suitable alternative is available, and in which case the 200 
medicine may be ordered from a Specials manufacturer (Specials medicine). Medicines legislation 201 
(specifically, The Medicines for Human Use Marketing Authorisations Etc Regulations 1994/SI 3144) 202 
states that medicinal products require a licence before they are marketed in the UK (19). 203 
Pharmacists felt that providing Certificates of Analyses to assure the safety and stability of Specials 204 
medicines and also licensing some medicines not commercially available in child appropriate 205 
formulations should be considered in order to improve medicines for children. Improving Specials 206 
medicines was not reported as an ideal medicine improvement by the nurses or medical 207 
practitioners, suggesting that this problem is not such a concern for them. 208 
Calpol® (paracetamol) suspension was presented as a favourite, well-liked medicine formulation in 209 
all of the groups. 210 
Problems related to medicines administration 211 
All groups discussed ad hoc manipulation techniques that had been reported to them by parents and 212 
carers and also those that they recommend to parents and carers to facilitate the administration of 213 
medicines to children (see figure 1). 214 
 215 
Manipulation techniques were discussed in detail by the nurses. The nurses provided examples of 216 
medicines manipulation on wards and also highlighted how parents administer medicines at home. 217 
Pharmacists showed most concern regarding pharmacokinetic effects. An example of this was their 218 
unanimous appreciation of mixing medicines with food-stuffs (i.e. orange juice), and the potential 219 
effects of altering pH on the drug. The nurse group also highlighted risks of altering drug stability 220 
when mixing medicines with substrates prior to administration. The medical practitioners reported 221 
more information on what parents actually do to the medicines. 222 
Non-sensory themes 223 
Frequent issues experienced when treating paediatric patients, the supply of 224 
medicines and liquid measuring devices 225 
“..the things I dread are when we have all these weird and wonderful specials” (Pharmacist 1 UHCW) 226 
The problems with Specials and unlicensed medicines were discussed in all groups and extensively 227 
amongst the pharmacists. Issues with omeprazole liquid Special were identified across the groups, 228 
these included problems regarding: obtaining, costing (between £100 and £120), GP prescribing 229 
(with reference to Primary Care Trust (PCT) guidance described first-hand by the GP in the medical 230 
practitioners group, in relation to budget), storage and short expiries. An alternative omeprazole 231 
formulation is Losec® MUPS (omeprazole) tablets. Problems with Losec® MUPS (omeprazole) 232 
blocking feeding tubes were highlighted in all groups. 233 
Problems with Specials medicines were a main focus of the pharmacist groups. Pharmacists 234 
demonstrated their increased knowledge, awareness and enthusiasm regarding Specials medicines. 235 
They discussed a variety of problems surrounding Specials which they frequently experienced first-236 
hand (e.g. unpredictable bioequivalence between different Specials medicines) compared to the 237 
medical practitioners and nurses. The medical practitioners seemed to have the least understanding 238 
and knowledge of the depth of issues with Specials and tended to identify Specials medicines and 239 
issues with supply. The medical practitioner group suggested that some pharmacists may not be 240 
aware that certain medicines can be ordered and query whether pharmacists remind patients about 241 
the shortened expiries of Specials medicines and the need to frequently re-order. The nurses 242 
expressed their concern towards extemporaneously dispensed products and the inconvenience of 243 
frequent journeys to hospital pharmacy. 244 
Parental understanding of medicines 245 
Parental influence on medicines adherence and also limited parental understanding of medicines 246 
was reported across all healthcare professional groups. The nurses emphasised the need for 247 
parental education, whilst the BCH pharmacist group acknowledged the limited time available to 248 
counsel patients effectively, resulting in their reliance upon nursing staff. Incorporating appropriate 249 
information in to clinic appointments for parents, carers and children could improve the safety and 250 
effectiveness of medicines use and also reduce medicines non-adherence. 251 
‘Pill-swallowing training’ for groups of patients with specific chronic conditions was discussed by the 252 
nurses and pharmacists. Mandatory ‘Pill-swallowing training’ for all children of a specific age was 253 
reported to be implemented in Australia (no reference was provided with these reports). 254 
The UHCW pharmacist group highlighted the plethora of social issues that prevail in the domiciliary 255 
setting, implying that medicines adherence is not always prioritised in some social circumstances. 256 
Medicines adherence  257 
Pharmacists, medical practitioners and nurses reported that dosage form preference is influenced by 258 
individual patient choice. The groups contended that parents can influence dosage form choice and 259 
medicines adherence in paediatric patients. Reports of parents and carers influencing medicines 260 
adherence in paediatric patients were frequently addressed in all groups. This included parents not 261 
allowing young people empowerment and also parents not supporting medicines adherence. 262 
 263 
The value of rationalising medicines in children who are prescribed multiple medicines 264 
(polypharmacy) was proposed by a medical practitioner and BCH pharmacist. On the topic of 265 
extemporaneous medicines, the pharmacists reported their unanimous negative attitude towards 266 
preparation within community pharmacies and compared this to the rigorous approach adopted 267 
within hospital pharmacies. The nurses discussed problems with short expiries of extemporaneous 268 
preparations (sodium phosphate and sodium chloride solution), thus leading to inconveniences for 269 
parents owing to frequent hospital visits. 270 
Adverse effects of medicines  271 
The medical practitioners and nurses identified key adverse effects of medicines with which they 272 
were familiar.  273 
Concerns regarding the safety of excipients were at the forefront of the BCH pharmacist session, 274 
with specific reference to propylene glycol, alcohol, sweeteners and sugars. 275 
The supply of medicines and liquid measuring devices and medication errors 276 
Difficulty in freely obtaining oral syringes on the NHS was highlighted by all of the healthcare 277 
professional populations.  Nurse reports included comments on the reluctance of supply by 278 
pharmacists - inferring that this is a financial problem, parents having to purchase oral syringes and 279 
the paucity of oral syringe sizes available in the Drug Tariff. A medical practitioner addressed the 280 
disallowance  of prescribing oral syringes on FP10 prescriptions and reported lack of knowledge 281 
regarding whether pharmacists are allowed to freely provide oral syringes or if it is out of their own 282 
goodwill. 283 
In addition, the pharmacists highlighted the risks of using inaccurate measuring devices (reports 284 
included using a teaspoon). 285 
The UHCW pharmacists perceived that the labelling of liquid medicines should be standardised, for 286 
example, labelling all liquid medicines as the weight of drug in the same volume (i.e. Xmg in 1ml). 287 
Both healthcare professionals and parents can become confused when different strengths are 288 
printed on medicine labels and examples of this were provided by the UHCW pharmacists. 289 
The risk of medication selection errors at GP practices was identified in the UHCW pharmacist focus 290 
group. 291 
Problems with medicines at school 292 
Problems with medicines at school were reported across the groups. Unanimous reports suggested 293 
that medicines should be prescribed to be administered outside of the school day (where this is 294 
possible).  295 
Discussion 296 
Sensory characteristics: Taste, texture, size of solid dosage form, and volume were common themes 297 
discussed in all of the focus groups. Problems with taste were reported most often. Oral flucloxacillin 298 
was highlighted across all groups to be poorly accepted owing to palatability. One study similarly 299 
reported that oral flucloxacillin is often considered unpalatable by children and suggested 300 
conducting a taste-test with an individual child prior to prescribing flucloxacillin solution (20). Chloral 301 
hydrate solution, prednisolone soluble tablets and Movicol® oral powder were all highlighted with 302 
respect to taste in two of the focus groups. Similar findings were reported in other studies; oral 303 
chloral hydrate (21), and taste of prednisolone oral solution superior to crushed tablets (22).  304 
 305 
All healthcare professional groups reported texture as a barrier to medicines administration; 306 
particularly amongst children with learning disabilities. Field and co-workers (2003) defined five 307 
feeding problems (including one related to the texture of foodstuffs) and explored pre-disposing 308 
factors to these problems. Over one quarter of children suffering from Down’s syndrome, autism or 309 
cerebral palsy refused to eat food textures that were considered to be developmentally appropriate 310 
(23). Feeding problems (including those related to texture) should be considered carefully by 311 
prescribers prior to making prescribing decisions. 312 
 313 
The size of solid dosage forms was a common theme highlighted across the groups. Several studies 314 
investigating children suffering from HIV support these findings and have reported the negative 315 
attitudes of children regarding the size of antiretroviral tablets (24-30). 316 
 317 
The nurses shared an in-depth knowledge on oral formulation-related barriers to medicines 318 
administration that the medical practitioners and pharmacists did not discuss, highlighting the 319 
importance of conducting focus groups with different healthcare professionals. This plethora of 320 
knowledge mirrors the ‘hands-on’ experience that nurses have on administering medicines to 321 
children. See table 1 for reports on the variety of formulation-related issues discussed across the 322 
groups. 323 
 324 
The pharmacists perceived that an improvement to Specials medicines would be ideal. Pharmacists 325 
felt that providing Certificates of Analyses to assure the safety and stability of Specials medicines and 326 
also licensing some medicines not commercially available in child appropriate formulations should 327 
be considered in order to improve medicines for children. Improving Specials medicines was not 328 
reported as an ideal medicine improvement by the nurses or medical practitioners, suggesting that 329 
this problem is not such a concern for them. Supporting these findings, one study investigated the 330 
opinions of GPs regarding off-label prescribing and found that less than 15% of GPs admitted to 331 
specific concerns when prescribing off-label, including the risk of adverse effects and unevaluated 332 
efficacy  (31). Calpol® suspension was described positively across all groups; this is supported by 333 
previous documentation stating that fruity, sweet formulations are preferred and in general citrus 334 
and red berry flavours are favoured across Europe (32). Pharmaceutical companies should be fully 335 
aware of medicines that are generally well-accepted by the paediatric population.  336 
 337 
Study findings indicate that paediatric pharmacists’ knowledge on risks of medicines manipulation 338 
was better than that of the allied healthcare professionals in this study. This suggests that the 339 
knowledge of paediatric pharmacists should be used to guide and educate healthcare professionals 340 
when prescribing or administering medicines in paediatric patients. Communication is crucial and 341 
each healthcare professional group should be utilised for the wealth of their knowledge, for example 342 
it may be beneficial for medical practitioners and nurses to seek advice from hospital pharmacists on 343 
drug-foodstuff incompatibilities. To support this, the knowledge and education of paediatric 344 
pharmacists should be addressed to ensure that they have optimal understanding of key scientific 345 
properties that may affect the dissolution and disintegration of a dosage form, properties including 346 
the fat and dairy-protein content, pH and solubility of foodstuffs (12) Such factors, in addition to 347 
food affecting gastric emptying rate, risk altering the bioavailability of a drug (33).  348 
 349 
A plethora of medicines manipulation techniques were discussed in this study; similar practices have 350 
been reported in previous studies (34,35). Findings of the focus groups indicate that the participating 351 
healthcare professionals were unaware of the level of evidence supporting various ad hoc 352 
manipulation techniques. Similar to the present study, one study observed that the majority of 353 
nurses were unaware of potential drug stability and degradation issues when performing ad hoc 354 
administration techniques and additionally some nurses were not conscious of a possible impact 355 
upon clinical outcome (12). Further laboratory work is warranted to provide a robust scientific 356 
evidence base to support safe and effective medicines manipulation; it should be recognised that 357 
existing resources currently exist which provide guidance on medicines manipulation  (36,37). 358 
 359 
The risks of medicines interacting (through binding) with nutritional feeds and the potential effects 360 
on drug absorption were discussed by the pharmacists and nurses. Examples provided were 361 
phenobarbital, phenytoin and ciprofloxacin. Nurses declared their uncertainty regarding how and 362 
when to administer the calcium binding drug ciprofloxacin, highlighting that advice is needed when 363 
administering medicines and nutritional feeds to optimise therapy. More scientific evidence, based 364 
on laboratory work investigating interactions between medicines and nutritional feeds (i.e. 365 
identifying potential insoluble complex formation) should be used to direct and standardise 366 
pharmaceutical advice in addition to sources that are already available, e.g. (38). It would be useful 367 
to translate this scientific evidence in to appropriate sources for nurses and parents and carers. 368 
 369 
The pharmacists had greater knowledge and understanding of Specials medicines compared to the 370 
nurses and medical practitioners. Similarly, several studies have identified differences in the 371 
knowledge on Specials, off-label and unlicensed medicines between allied healthcare professionals 372 
(13,14,39). Further investigation is necessary to address the education and support that is needed to 373 
improve knowledge of unlicensed medicines, Specials and off-label prescribing amongst healthcare 374 
professionals. Educating doctors and allied healthcare professionals on the appropriate use of 375 
Specials medicines at degree or equivalent level is fundamental to improving their understanding of 376 
unlicensed medicines and optimising safe and cost-effective prescribing practices. 377 
 378 
Improving time organisation to permit pharmacists to counsel patients effectively could help to 379 
minimise problems that result from poor parental understanding as reported in the focus groups. 380 
Pharmacists identified that staff shortages were a barrier to counselling patients. Government 381 
funding bodies need to consider this when calculating financial budgets available to the NHS.  382 
Several studies investigating solid dosage form training have found improvements in swallowing 383 
abilities amongst children diagnosed with HIV (24,25). This may help to minimise difficulties with 384 
tablet size and also support the use of novel formulations, e.g. mini-tabs (40,41) in paediatric 385 
patients who would not generally be prescribed a tablet until they are older.  386 
 387 
This study identified that family-related factors (including ‘social circumstances’) can influence 388 
medicines adherence in children, this is supported by other studies (42-45).  The impact of 389 
polypharmacy on medicines adherence requires further investigation. The importance of medicines 390 
adherence should be thoroughly explained to parents and children especially in circumstances 391 
where an improvement of a chronic condition is not apparent. This may help to discourage parents, 392 
carers and young people from discontinuing medicines without consulting healthcare professionals 393 
and through this improve medicines adherence.  394 
 395 
Study findings suggest that future work should investigate whether incorporating education for 396 
parents, carers and young people within clinic sessions, on common and minor adverse effects of 397 
medicines to support patients and manage their expectations of medicines has the potential to 398 
improve adherence. In addition, concerns regarding the safety of excipients need to be addressed. 399 
The draft guideline on pharmaceutical development of medicines for paediatric use (46) reinforced 400 
the requirement for pharmaceutical companies to carefully select excipients when formulating 401 
medicines for children. The final decision to include an excipient should be evaluated using a benefit 402 
to risk ratio of the end pharmaceutical product (47). It should be recognised that some studies have 403 
reviewed stability evidence and provide information regarding formulations and excipients (48,49). 404 
 405 
Issues revealed with the supply of oral syringes on the NHS suggest that the Government should 406 
address NHS funding in this area. Concern regarding the use of innacurate measuring devices needs 407 
to be addressed. Household teaspoons can vary between 2ml and 10ml and thus using a teaspoon 408 
could result in a significant underdose or overdose (50). Pharmacists should be ensuring that the 409 
correct dosing instrument is supplied to all patients and that counselling is provided to parents and 410 
carers to assure accurate measurement of a dose. 411 
 412 
Standardising the labelling of liquid medicines was reported as a potential method to minimise some 413 
dosing errors. Studies are required to investigate if standardising the labelling of liquid medicines 414 
could significantly improve patient safety. It is prudent that medicines labelling guidance provided to 415 
pharmaceutical companies when applying for a Marketing Authorisation is addressed imminently. 416 
Reports that medication selection errors are a problem at GP practices, suggest that safeguarding 417 
measures and staff training need to be addressed. 418 
 419 
Reports across the groups of some schools refusing to accept responsibility for medicines suggests 420 
that medicines policies are not adopted uniformly across schools. Medicines adherence during 421 
school hours may be sub-optimal if schools do not support medicines administration. Omitting doses 422 
of medicines during the school day could have a significant impact on clinical outcome, therefore it is 423 
critical that medicines administration is addressed correctly in schools. This is especially important 424 
for paediatric patients suffering with chronic conditions and those requiring vital acute medicines.  425 
 426 
Study limitations 427 
Logistics created the greatest problem when recruiting participants. Time constraints resulting from 428 
staff shortages restricted the availability of healthcare professionals and affected study recruitment. 429 
A limitation of the focus group study was the low recruitment rate in the UHCW pharmacist group, 430 
as this represented more a nominal group. It is acknowledged that group interaction is inevitably 431 
minimised with low numbers of participants in a focus group. However, the information gathered 432 
from the UHCW pharmacist focus group in collaboration with the BCH pharmacist group widened 433 
the scope of pharmacist views in this study. 434 
 435 
Although some healthcare professionals in the same setting were known to each other, the nature 436 
of this focus group study was not perceived to be threatening; therefore it is unlikely that 437 
participants would have contributed in a manner deemed to be more socially acceptable. 438 
 439 
The study was conducted at two sites in the West Midlands, UK, therefore it cannot be generalised 440 
and viewed as a nationwide perspective. Further investigation is required. 441 
 442 
Conclusion 443 
In summary, this study has identified a large number of issues perceived by healthcare professionals 444 
to cause problems when administering oral medicines to children, however, these issues are not 445 
always considered when using medicines in children. Taste was highlighted as the most significant 446 
issue with specific examples, e.g.  flucloxacillin solution, being reported across all groups. 447 
 448 
Collaboration between doctors, nurses and pharmacists is essential to optimise patient care. Nurses 449 
had the greatest knowledge of bedside issues, whilst pharmacists understood the consequences of 450 
certain manipulations; wider sharing of this knowledge can help to ensure appropriate medicines are 451 
prescribed to minimise issues with administration. Communication is crucial and each healthcare 452 
professional group should be utilised for the wealth of their knowledge. 453 
 454 
Findings of this study suggest that a paucity of scientific evidence is available to support the many ad 455 
hoc manipulation techniques regularly used. Review of medicines manipulation data available in 456 
literature confirmed that a robust scientific evidence base requires further development; this needs 457 
to be addressed as it is evident that medical practitioners require more information when 458 
prescribing medicines to ensure supply, clinical effectiveness and to maximise cost efficiency.  459 
 460 
Addressing the education of healthcare professionals involved in prescribing, dispensing and 461 
administering oral medicines to children and additionally counselling provided to parents, carers and 462 
paediatric patients will be invaluable to improving the therapeutic treatment of paediatric patients. 463 
Protocols detailing best practice guidance need to be developed. Further studies exploring the views 464 
of healthcare professionals in different settings would complement this research.  465 
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Table 1 Thematic coding spine detailing thematic headings and thematic sub-headings 615 
Thematic headings Thematic sub-headings 1 Thematic sub-headings 2 
Sensory themes   
Oral formulation-related 
barriers to medicines 
administration 
 
 Taste-related problems 
*Gastrografin® (sodium diatrizoate/meglumine diatrizoate) 
solution – Nurse 4. Oramorph® (morphine sulfate) solution – 
Nurse 1. Septrin® (trimethoprim and sulfamethoxazole) 
paediatric suspension – Pharmacist 2 UHCW. Rifampicin 
suspension – Pharmacist 1 UHCW. Kaletra® (lopinavir/ritonavir) 
solution – MP 7 describes burning sensation. Nitrofuranotin 
Special suspension – MP 5. Clarithromycin suspension – MP 2. 
Generic paracetamol suspension – Nurse 2. 
 Problems with texture 
*Ciclosporin solution (pharmacist 1 UHCW described as oily). 
Lactulose solution (MP 1 described as oily). Topiramate sprinkle 
capsules (MP 1). Calcichew® (calcium carbonate) tablets (MP 2). 
Creon® (pancreatin) Micro gastro-resistant granules – 
inconvenience of transporting apple puree to mask texture (nurse 
4). 
 Problems with colour and smell 
*Rifampicin liquid – red colour described as “off-putting” (nurse 
1). Klean-prep® (macrogol ‘3350’) liquid – “smell makes you 
wretch, it’s horrible” (nurse 4). Abidec® vitamin drops – bad 
smell and the colour stains bibs, yet tolerated (nurse 4). 
'Horrendous feeds' and a smell that “pervades everything” (nurse 
1). 
 Problems with size and swallowing 
*Ethambutol tablets (pharmacist 2 described that often multiple 
small tablets are preferred). Slow sodium® (sodium chloride) 
tablets -“Like an old paracetamol tablet, they’re quite sticky to 
swallow down”   (nurse 4). Temozolomide tablets - “I think 
they’re quite big drugs” (nurse 6). Antiretroviral tablets (all 
groups). 
 Problems with quantity and volume 
*Chloral hydrate solution** described as having a “huge volume” 
(nurse 1 and pharmacist 1 UHCW). Movicol® (macrogol ‘3350’) 
oral powder*** (Pharmacists agree large volume). Soluble 
prednisolone tablets (nurse 3). Antiretroviral liquids -“liquid 
volumes are so high”   (MP 7). Administering considerable 
volumes of medicines in addition to feeds in neonates, voiced by 
nurse 3. 
 
 
 
 
 
Future medicines for children  Ideal improvements to medicines 
 Well-accepted medicines 
 
 
Problems related to medicines 
administration  
 Administration problems with specific medicines 
 Interactions with foodstuffs and sub-optimal drug 
absorption 
 Medicines manipulation 
 (The knowledge of healthcare 
professionals regarding 
physicochemical effects of 
medicines manipulation, 
Evidence base for medicines 
manipulation) 
Non-sensory themes   
Frequent issues experienced 
when treating paediatric 
patients 
 Specials medicines, unlicensed medicines and off-
label administration 
 Omeprazole formulations 
 The knowledge and understanding  of medical 
practitioners, pharmacists and parents regarding 
unlicensed medicine 
 Extemporaneous dispensing 
 
 
(Omeprazole liquid, Losec® 
MUPS- licensed omeprazole 
formulation)  
Parental understanding of 
medicines 
 Educating parents and children about medicines 
 Social problems and language barriers 
 
 
Medicines adherence 
 
 The relationship between age of child and dosage 
form preference 
 Parental influence on dosage form choice and 
medicines adherence 
 The relationship between age of child, disease 
status, diagnosis, miscellaneous variants and 
medicines adherence 
 Polypharmacy  
 
Adverse effects of medicines  Excipients  
  Adverse effects associated with specific medicines 
The supply of medicines and 
liquid measuring devices 
 Problems with the supply of oral syringes and the 
accuracy of measuring liquid medicines 
  
 
 
Medication errors in 
pharmacies and GP practices 
 Standardising the labelling of liquid medicines 
 Medicine selection errors at GP practices 
 
Problems with medicines at 
school 
 Problems with medicines at school  
*Problems with specific medicines or groups of medicines, as reported by the healthcare professionals indicated. 616 
** Choral hydrate - dose for 1-12 year olds approximately 5-20mls ‘well diluted with water’ (18). 617 
*** Movicol® (macrogol ‘3350’) oral powder - each sachet added to 125mls of water (18). 618 
 619 
 620 
 621 
 622 
Figure 1: Examples of ad hoc administration techniques reported by the indicated healthcare professional groups. 623 
 624 
Medical 
Practitoners 
•Epilim® (sodium  valproate) granules on 
jam on toast 
•Mix in blackcurrant/ orange juice/milk, 
crush it in to jam or yoghurt 
•Give a sweet after flucloxacillin 
•Prednisolone  soluble tablets mixed with 
neat ribena  
•Methotrexate and mercaptopurine 
tablets “I’m sure they must get crushed 
up those”  
•Melatonin “I’ll always say yoghurt, the 
advice I would normally give, put it in 
yoghurt and do that immediately before 
you go to bed because it denatures 
before... and don’t use it in hot food”  
 
 
 
Nurses 
•Yoghurt with crushed medicines  
•Use strong flavours to mask- 
gastrografin® (sodium 
diatrizoate/meglumine diatrizoate); coke 
or ribena  
•Soluble prednisolone in minimal water 
•Creon ® (pancreatin) Micro gastro-
resistant granules in apple puree to mask 
texture 
•"The Movicol ® (macrogol '3350') rep says 
you can put it into jellies and things"  
•In reference to Movicol® (macrogol 
'3350'):  “People hide it in their dinners.. 
their mash potato..”  
•  Warm water to dissolve Losec® 
(omeprazole)  MUPS  
•‘Not x goes with y, just try whatever the 
child likes’ 
Pharmacists 
•Creon® (pancreatin) Micro gastro-
resistant granules with a spoonful of 
breast milk, apple puree or baby rice  
•"Ciclosporin you can mix with stuff" 
•Grinding tablets and mixing with yoghurt 
or dissolving in water (mercaptopurine) 
•Liquid paraffin and ice-cream 
recommended as a technique to numb 
taste buds 
•“Stick in a bit of yogh- put it in a bit of 
banana or something like that you  can A 
slip things down if you’ve got something 
that’s a bit harder to take” 
•‘Get down them in any way’ 
•Losec® (omeprazole) MUPS with squash 
and juice 
•Topamax® (topiramate) sprinkle  on 
foodstuffs 
•Before dispersible tablets were available, 
recommended opening capsules of 
melatonin or dispersing them in yoghurt 
•  Movicol® (macrogol '3350') oral powder 
advice.. “in apple puree and stuff.” 
Mixing advice is provided in drug 
information sheets, but is not referenced.  
